Real and assumed potential savings in antihypertensive treatment. Right out of the magician's hat;Echte und vermeintliche sparpotenziale in der hochdrucktherapie neues aus dem zauberhut

Deutsche Medizinische Wochenschrift

Volumn 128, Issue 28-29, 2003, Pages 1557-1559

  Anlauf, Manfred ^a,c   Hense, H W ^b  

^a Medizinische Klinik II   (Germany)

^b Inst fur Epidemiol/Sozialmedizin   (Germany)

^c Medizinische Klinik II   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; LISINOPRIL;

ANTIHYPERTENSIVE THERAPY; COST CONTROL; EVIDENCE BASED MEDICINE; GERMANY; HUMAN; HYPERTENSION; NOTE; PRACTICE GUIDELINE; STANDARD;

ANTIHYPERTENSIVE AGENTS; COST SAVINGS; DIURETICS; DRUG COSTS; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; NATIONAL HEALTH PROGRAMS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0038104276     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-40387     Document Type: Note

References (10)

1. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283: 1967-1975
2. ALLHAT Officers and Coordinators for the ALLHAT. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997
3. Anlauf M. ACE-Hemmer und Angiotensinrezeptorantagonisten. Springer-Verlag Berlin, In: Schwabe U, Paffrath D (Hrg). Arzneiverordnungsreport 2002. 2002: 67-88
4. Chobanian AV, Bakris GL, Black HR, Cushman WC et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289: 2560-2571
5. Düsing R. Alte oder neue Antihypertensiva? Konsequenzen aus ALLHAT. Dtsch Med Wochenschr 2003; 128: 214-216
6. Gæde P, Vedel P, Larsen N, Jensen GVH et al. Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes. N Engl J Med 2003; 348: 383-393
7. Neal B, MacMahon S, Chapman N for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 356: 1955-1964
8. Wehling M. Kommentar zur ALLHAT-Studie (Leserbrief). Dtsch Med Wochenschr 2003; 128: 1252
9. Wing LMH, Reid MC, Ryan P, Beilin LJ et al. for the Second Australian National Blood Pressure Study Group. A Comparison of Outcomes with Angiotensin-Converting Enzyme Inhibitors and Diuretics for Hypertension in the Elderly. NEJM 2003; 348: 583-592
10. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW et al. Hypertension Prevalence and Blood Pressure Levels in 6 European Countries, Canada, and the United States. JAMA 2003; 289: 2363-2369